Sarcopenic obesity, defined as the coexistence of low muscle mass and high body fat, is increasingly recognized among cancer patients, particularly those undergoing breast cancer treatment. It is estimated that about 20% of cancer patients are affected by this condition. In patients with breast cancer, sarcopenic obesity contributes to poorer prognoses due to increased treatment-related complications and comorbidities.

The Link Between Sarcopenic Obesity and Chemotherapy Toxicity

Sarcopenia is closely associated with chemotherapy-related toxicity and reduced survival in women with breast cancer. The dual burden of muscle loss and fat gain leads to functional decline, increased treatment complications, and ultimately, worse outcomes. In breast cancer patients, muscle loss in cancer patients due to sarcopenia combined with obesity amplifies inflammation and metabolic disruption, worsening the patient’s health status.

Biological Mechanisms Underlying Sarcopenic Obesity

Obesity, a chronic low-grade inflammatory state, contributes to altered cytokine and adipokine levels, such as elevated IL-6, MCP-1, TNFα, and leptin, and reduced adiponectin. These inflammatory mediators are key drivers of muscle degradation and muscle loss in cancer patients. Furthermore, cancer itself accelerates metabolic imbalances through cachexia and aging, promoting continued muscle loss and increasing patient vulnerability.

Impact of Cancer Treatment on Body Composition

Both cancer and its treatment significantly alter body composition, often causing loss of lean muscle mass alongside fat gain. These changes are particularly concerning in elderly patients, who are more likely to experience frailty and reduced independence. The cycle of sarcopenia, increasing chemotherapy toxicity, and treatment further aggravating muscle loss, needs focused intervention.

Evaluating Sarcopenic Obesity at Sammprada

At Sammprada, we emphasize the evaluation of sarcopenic obesity as a critical indicator of poor outcomes in breast cancer treatment. This includes using advanced imaging techniques like CT scans to assess:

• Skeletal Muscle Mass (SMM)
  
• Visceral Adipose Tissue (VAT)
  
• Subcutaneous Adipose Tissue (SAT)
  
• Inter-muscular Adipose Tissue (IMAT)
  

These indices help in accurately understanding body composition and designing personalized treatment strategies.

Addressing Sarcopenic Obesity Through Targeted Interventions

There is an urgent need for targeted metabolic strategies combined with pharmacologic and lifestyle modifications to counter sarcopenic obesity. These include:

• Resistance and aerobic exercises to increase muscle mass
  
• Nutritional strategies emphasizing protein intake and quality
  
• Combined interventions showing synergistic effects in enhancing strength, function, and treatment response
  

Such strategies are especially beneficial for older patients and those at high risk for adverse treatment outcomes.

The Indian Context: A Call for Data and Research

In India, there is a notable gap in data regarding the impact of cancer treatment on body composition. This highlights the importance of integrating sarcopenia and sarcopenic obesity assessment into routine cancer care. The work at Sammprada aims to provide evidence for how nutrition and physical activity interventions can improve outcomes before, during, and after cancer treatment.